Somerville, MA, United States of America

Michael Charles Hewitt

USPTO Granted Patents = 33 (Patent Applications = 7)

CIPO Patents = 8 (Patent Applications = 3)

EPO Patents = 17 (Patent Applications = 15)

Average Co-Inventor Count = 5.1

ph-index = 7

Forward Citations = 161(Granted Patents)

Location History:

Cambridge, MA (US) (2011 - 2019)
Brookline, MA (US) (2014 - 2019)
Somerville, MA (US) (2011 - 2021)

Company Filing History:

21 out of 130

Sunovion Pharmaceuticals Inc.

patents

11 out of 54

Constellation Pharmaceuticals, Inc.

Pgi Drug Discovery LLC

Massachusetts Institute of Technology

patents

where one patent can have more than one assignee

Years Active: 2011-2021

where 'Filed Patents' based on already Granted Patents

33 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10894033 - Multicyclic compounds and methods of use thereof (2021-01-19),

2. 10570156 - Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors (2020-02-25),

3. 10562916 - Substituted quinoxalines as PDE-10 inhibitors (2020-02-18),

4. 10562878 - Cycloalkylamines as monoamine reuptake inhibitors (2020-02-18),

5. 10457640 - Synthesis of inhibitors of EZH2 (2019-10-29),

6. 10428021 - Triple reuptake inhibitors and methods of their use (2019-10-01),

7. 10258603 - Therapeutic compounds and uses thereof (2019-04-16),

8. 10206931 - Therapeutic compounds and uses thereof (2019-02-19),

9. 10183009 - Therapeutic compounds and uses thereof (2019-01-22),

10. 10150767 - Therapeutic compounds and uses thereof (2018-12-11),

11. 10085968 - Multicyclic compounds and methods of use thereof (2018-10-02),

12. 9925197 - Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof (2018-03-27),

13. 9868718 - Cycloalkylamines as monoamine reuptake inhibitors (2018-01-16),

14. 9856274 - Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors (2018-01-02),

15. 9850204 - Triple reuptake inhibitors and methods of their use (2017-12-26),

Title: Innovator Spotlight: Michael Charles Hewitt - Pioneering Neurological Treatments

Introduction: Michael Charles Hewitt, a prolific inventor based in Somerville, MA (US), has made significant contributions to the field of pharmaceuticals with a total of 33 patents to his name.

Latest Patents: Among his latest patents are groundbreaking innovations such as multicyclic compounds for the treatment of neurological disorders like psychosis and schizophrenia, as well as substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors for central nervous system and metabolic diseases.

Career Highlights: Michael has lent his expertise to renowned companies like Sunovion Pharmaceuticals Inc. and Constellation Pharmaceuticals, Inc., where his inventive spirit and dedication to advancing medical treatments have shone through.

Collaborations: Throughout his career, Michael has collaborated with esteemed coworkers such as Liming Shao and John Emmerson Campbell, leveraging their collective knowledge to push the boundaries of pharmaceutical research and development.

Conclusion: In conclusion, Michael Charles Hewitt stands as a pioneering figure in the pharmaceutical industry, with a track record of transformative inventions that have the potential to positively impact the lives of individuals suffering from various neurological conditions. His dedication to innovation and commitment to advancing medical treatments make him a true trailblazer in the field.

This text is generated by artificial intelligence and may not be accurate.